Katie E. Hyma, Ph.D., counsels clients in a wide range of technologies, primarily in the life sciences, with an emphasis on biotechnology, molecular biology, and therapeutics. Her clients include emerging biotechnology startups, established companies with well-developed intellectual property portfolios, venture capital firms, and world-class academic medical and research facilities.

Katie helps her clients to identify, protect, and optimize the value of their IP with a focus on patent prosecution and counseling, as well as post-grant proceedings. She also advises clients in all phases of due diligence, including mergers and acquisitions, fundraising, and IPOs. Katie performs portfolio analyses, identifies third-party patent risks, and provides patentability and freedom to operate opinions. Her clients appreciate her ability to distill complex information and ideas into an understandable and actionable format.

Katie has broad research experience in evolutionary biology, population genetics, bioinformatics, ecology, microbiology, and molecular genetics. Before practicing law, she worked at Cornell University’s Institute for Biotechnology, where she developed and implemented novel pipelines for genetic mapping in grapevine and assisted researchers with project design, planning, and data analysis. Katie has published papers in molecular ecology, theoretical and applied genetics, PLOS One, and BMC Genomics, among others, and has provided training in cutting-edge genotyping technologies to scientists around the world.